<?xml version="1.0"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
    "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <meta name="generator"
    content="HTML Tidy for FreeBSD (vers 1st April 2002), see www.w3.org" />
    <base
    href="http://www.cirp.org/library/disease/balanitis/albertini1/" />

    <title>Zoon&rsquo;s Balanitis Treated with Erbium:YAG Laser
    Ablation</title>
    <meta name="robots" content="index, follow" />
    <meta name="keywords"
    content="laser surgery, Zoon's balanitis, Plasma cell balanitis, men's health, Erbium:YAG laser, Carbon dioxide laser, CO2 laser, men, male health, males, penis" />
    <meta name="description"
    content="A medical journal article about conservative treatment of Zoon's balanitis." />

    <style type="text/css">
    /*<![CDATA[*/
<!--
body 
{
background-color: white;
color: black;
}
div.corpus
{
margin-left: 1.0in;
margin-right: 1.0in;
}
h4
{
text-align: center;
}
p.key
{
text-align: center;
font-size: 10pt;
}
p.cirp
{
font-weight: bold;
color: navy;
margin-left: 1in;
margin-right: 1in;
}
p.topic
{
font-size: 14pt;
text-align: center;
}
p.text
{
font-size: 11pt;
text-indent: 2em;
text-align: justify;
}
p.notes
{
margin-left: 156;
font-size: 10pt;
text-indent: -156;
}
p.reprints
{
font-size: 10pt;
}
p.navlink
{
text-align: center;
}
li.note
{
font-size: 10pt;
text-align: justify;
}
sup
{
font-size: 8pt;
}
sub
{
font-size: 8pt;
}
span.yellow
{
background-color: #ff9;
}
-->
    /*]]>*/
    </style>
  </head>

  <body bgcolor="white">
    <h3>LASERS IN SURGERY AND MEDICINE, Volume 30, Number 2: Pages
    123-6,<br />
    8 February 2002.</h3>
    <br />
    <br />

    <div class="corpus">
      <h2>Zoon&rsquo;s Balanitis Treated with Erbium:<br />
      YAG Laser Ablation</h2>

      <p><b>John G. Albertini, MD, Maj, USAF, MC<br />
      David E.E. Holck, MD, LtCol, USAF, MC<br />
       Mary F. Farley, MD, LTC, USA, MC</b></p>

      <p>Department of Dermatology<br />
      <a href="http://www.bamc.amedd.army.mil/"
      target="_blank">Brooke Army Medical Center</a><br />
      Fort Sam Houston, TX 78234 (JGA, MFF)</p>

      <p>Department of Ophthalmology<br />
      <a href="http://www.whmc.af.mil/">Wilford Hall USAF Medical
      Center</a><br />
      Lackland AFB, TX 78236 (DEEH)</p>
      <br />

      <h4>ABSTRACT</h4>

      <p><b>Background and Objective:</b> Zoon&rsquo;s balanitis
      (ZB) is an uncommon, benign, idiopathic inflammatory
      condition affecting uncircumcised males. Definitive
      treatments include circumcision and acarbon dioxide
      (CO<sub>2</sub>) laser ablation. We describe an alternative
      laser modality showing efficacy in the treatment of ZB.</p>

      <p><b>Study Design/Materials and Methods:</b> We report the
      first case of ZB effectively treated with Erbium:YAG (Er:YAG)
      laser ablation. We review the pathogenesis and medical,
      surgical and laser management of ZB.</p>

      <p><b>Results:</b> Our patient demonstrated a long-term
      clinical and histologic cure after Er:YAG laser ablation of
      ZB.</p>

      <p><b>Conclusions:</b> <span class="yellow">As an alternative
      to circumcision or continuous wave CO<sub>2</sub> laser, we
      propose a trial of Er:YAG laser ablation as a low risk, first
      line treatment of ZB.</span></p>

      <p class="key">Key Words: Carbon dioxide laser, Plasma cell
      balanitis, Erbium:YAG laser</p>

      <p class="cirp">[CIRP Note: This file does not include four
      illustrations published with the article.]</p>
      <br />

      <h4>INTRODUCTION</h4>

      <p class="text">Zoon&rsquo;s balanitis (ZB), also known as
      plasma cell balanitis, is a relatively uncommon, idiopathic
      inflammatory condition. ZB primarily affects the glans penis
      in uncircumcised males, who present with red-orange, smooth
      or eroded plaques.<sup><a href="#n1">1-10</a></sup> ZB
      occasionally causes pruritis or discomfort. CO<sub>2</sub>
      laser ablation of ZB is an effective treatment<sup><a
      href="#n11">11</a></sup> and may be preferable to
      circumcision<sup><a href="#n10">10,12,13</a></sup> in the
      management of this disease. We present a case illustrating
      that superficial laser ablation with a newer generation of
      resurfacing lasers may be as effective as traditional
      continuous-wave CO<sub>2</sub> ablation, with less morbidity,
      thermal damage and risk of scarring.</p>
      <br />

      <h4>CASE REPORT</h4>

      <p class="text">The Urology department referred a 67 year-old
      Caucasian male for treatment of squamous cell carcinoma
      in-situ or erythroplasia of Queyrat (EQ) of the glans penis.
      He was clinically diagnosed with EQ in 1988 and treated with
      5-fluorouracil cream (5-FU). Local recurrence in 1991 was
      biopsied and showed EQ. CO<sub>2</sub> laser ablation was
      performed, and repeated in 1993 for another local recurrence.
      Following these procedures, he was treated twice more with
      5-FU topically and appeared to clear completely. His
      presenting eruption evolved for several months prior to his
      Urology evaluation. Examination revealed a 23 x 17 mm smooth,
      brick-red, perimeatal plaque (Figure 1). His medical history
      and cutaneous examination were otherwise unremarkable.</p>

      <p class="text">The clinical differential diagnosis included
      plasma cell balanitis/Zoon&rsquo;s balanitis (ZB), psoriasis,
      and candidiasis, in addition to EQ. Shave biopsy was
      consistent with ZB, showing characteristic histologic
      features of a thinned, effaced epithelium overlying a dense,
      lichenoid plasma cell infiltrate, telangectasias and
      hemosiderin deposition. The patient failed 5 months of
      topical treatment with potent corticosteroids and mupirocin
      ointment. After <span class="yellow">the patient requested
      alternatives to circumcision</span>, we treated the balanitis
      with Er:YAG laser ablation (Derma-K, ESC Sharplan, 2940 nm,
      350 ms).</p>

      <p class="text">After EMLA application and local infiltration
      of 1% plain lidocaine, we treated the balanitis with 3-6
      overlapping passes using the lowest power settings (0.5
      J/cm<sup>2</sup>; 3 mm spot size; 5 Hz) (Figure 2,3). He
      healed well and completely reepithelialized within one week.
      A confirmatory shave biopsy after 2 months showed no residual
      balanitis. At 4 months, his exam revealed a perimeatal
      erythematous smooth plaque, which was retreated with 2 more
      passes of ablation (same settings). The plaque resolved and
      one month later a biopsy of the residual perimeatal erythema
      showed no evidence of ZB (Figure 4). He remains disease free
      after more than 2 years follow-up.</p>
      <br />

      <h4>DISCUSSION</h4>

      <p class="text">The exact etiology of ZB is unknown, but
      heat, friction and poor hygiene are considered pathogenic
      factors.<sup><a href="#n6">6,7</a></sup> Irritation by
      smegma, urine or external contacts and normal colonizing
      organisms that become pathogenic under favorable host
      conditions may also play a contributory role.<sup><a
      href="#n14">14,15</a></sup> The proclivity of ZB for the
      uncircumcised and the consistent response to circumcision
      lend support to this theory.<sup><a
      href="#n6">6-8,12</a></sup> In one case, incomplete
      circumcision cleared the majority of ZB, but resulted in
      persistent disease in the area of glans and prepuce still
      covered by foreskin.<sup><a href="#n12">12</a></sup> Chronic
      infection with <i>mycobacterium smegmatis</i> has been
      postulated as the cause of ZB. <sup><a
      href="#n15">15</a></sup> Recent attempts to isolate <i>m.
      smegmatis</i> have been unsuccessful.<sup><a
      href="#n8">8</a></sup> Yoganathan et al. conclude that trauma
      is most significant in the pathogenesis of plasma cell
      balanitis and vulvitis.<sup><a href="#n8">8</a></sup> They
      noted a concentration of disease on the dorsal glans penis,
      where foreskin friction is greatest. One of their female
      patients developed plasma cell vulvitis circumferentially
      around her vulva immediately after a traumatic vaginal
      delivery.</p>

      <p class="text">The unclear etiology of ZB and the multiple
      contributory factors make it difficult to find specific
      therapeutic targets. Promotion of good hygiene is an easy and
      potentially beneficial measure. Patients should be instructed
      to retract the foreskin regularly and perform gentle
      cleansing of the entire glans, preputial sac and foreskin.
      Many local, topical therapies have been reported, but rarely
      provide more than temporary control. Mid-potency and
      high-potency topical corticosteroids have been used for many
      years as a first line measure, producing variable clinical
      improvement but rarely long-term cures.<sup><a
      href="#n8">8</a></sup> Topical antimicrobial preparations
      including antibacterial and antifungal creams have largely
      proven ineffective. Fusidic acid is a combination
      anti-inflammatory and antibiotic agent sharing a similar
      molecular structure with corticosteroids. Fusidic acid 2%
      cream has induced both suppression and 6 month cures in 5 of
      8 patients, despite an unclear mechanism of action.<sup><a
      href="#n16">16</a></sup> Radiotherapy and local destructive
      modalities, such as electrosurgery, have rarely proven
      effective.</p>

      <p class="text">Circumcision has proven the most consistently
      effective, long-term cure for ZB.<sup><a
      href="#n7">7,10,12,13</a></sup> In 1984, Ferrandiz and Ribera
      reported cures in seven consecutive patients undergoing
      circumcision for ZB, with an average follow-up of 12
      months.<sup><a href="#n12">12</a></sup> Murray et al cured
      five consecutive patients with circumcision, two of whom had
      previously failed a dorsal slit procedure. <sup><a
      href="#n7">7</a></sup> Urologists may regard circumcision as
      the treatment of choice.<sup><a href="#n17">17</a></sup></p>

      <p class="text">In 1989, <span class="yellow">CO<sub>2</sub>
      laser ablation was reported as an effective alternative to
      circumcision.</span><sup><a href="#n11">11</a></sup> They
      used the defocused mode of the continuous wave CO<sub>2</sub>
      laser at an irradiance of 200W/cm<sup>2</sup> to produce
      &ldquo;highly precise vaporization&rdquo; and
      &ldquo;selective damage of the target area [ZB]&rdquo;.
      (Baldwin HE, Geronemus RG, p.493) The continuous wave
      CO<sub>2</sub> laser, however, carries a significant risk of
      scarring because its prolonged tissue dwell-time causes
      collateral thermal damage (200-300 mm).<sup><a
      href="#n18">18,19</a></sup> Irradiation of the skin surface
      by the Er:YAG laser produces relatively pure ablation with
      minimal thermal damage.<sup><a href="#n19">19-24</a></sup>
      Because ablation is directly proportional to fluence, the
      Er:YAG laser can be finely adapted to the clinical scenario.
      Several studies demonstrate that superficial cutaneous wounds
      produced by the Er:YAG laser or cold steel surgery
      reepithelialize at equivalent rates and without
      scarring.<sup><a href="#n25">25-27</a></sup></p>

      <p class="text">Ablation depth varies with laser and tissue
      properties, but with the short-pulsed (~100-300
      <i>&micro;</i>s) Er:YAG laser above the ablative threshold
      (~1.5 J/cm<sup>2</sup>), single impacts generally ablate 5-50
      <i>&micro;</i>m with residual thermal damage measuring 5- 40
      <i>&micro;</i>m.<sup><a href="#n19">19-25,28-35</a></sup>
      These ablation and coagulation depths apply for typical
      dermatologic settings (1-10 J/cm<sup>2</sup>). While the
      fluence (0.5 J/cm<sup>2</sup>) used in our patient is below
      the standard ablation threshold for keratinizing human skin,
      it approaches the range for guinea pig skin (0.6-1.5
      J/cm<sup>2</sup>).<sup><a href="#n20">20</a></sup> This
      fluence and the highly overlapping pattern appeared
      sufficient to superficially ablate mucosal epithelium, which
      lacks a hydrophobic orthokeratotic stratum corneum, which may
      have a slightly higher water content due to increased
      intracellular glycogen, and which may possess slightly weaker
      structural integrity than typical epidermis. Our mechanical
      wiping may also have contributed to the removal of some
      thermally denatured, non-vaporized, epithelium. While our
      clinical and pathological results confirm the efficacy of our
      parameters and technique, using a definitively ablative
      fluence may prove more efficient for treating this
      process.</p>

      <p class="text">The Er:YAG laser emits energy in the
      mid-infrared invisible light spectrum with a wavelength of
      2940 nm, which corresponds closely with an absorption peak
      for water.<sup><a href="#n36">36</a></sup> The peak water
      absorption coefficient is 13 times greater for the Er:YAG
      than for the CO<sub>2</sub> laser.<sup><a
      href="#n20">20,37</a></sup> Epidermis is composed of
      approximately 70% water by volume, making it highly
      susceptible to ablation with the Er:YAG laser.<sup><a
      href="#n21">21</a></sup> Because epidermal ablation is so
      efficient, peripheral thermal damage is limited to a very
      narrow zone. Recent work has shown that repetitive Er:YAG
      laser irradiation with pulse-stacking of low fluences can
      cause deep coagulation of dermal collagen.<sup><a
      href="#n38">38</a></sup> When treating ZB, proper technique
      should prevent this effect and scarring is unlikely because
      bleeding serves as a safeguard against deep ablation. Despite
      the highly vascular penile tissue, our negligible
      intra-operative bleeding demonstrates the precise and
      superficial ablation possible with the Er:YAG laser. ZB
      represents an epithelial process and the glans penis lacks
      adnexal structures that might harbor residual disease and
      that contribute to reepithelialization. Deep ablation is
      neither necessary nor desirable. The focal perimeatal
      recurrence likely resulted from mild urethral extension and
      it was easily retreated. Finally, smoke evacuation and
      properly fitted and filtered masks are critical in this
      setting because of the significant plume produced and the
      risk of subclinical pathogenic microorganisms on genital
      skin.</p>
      <br />

      <h4>CONCLUSION</h4>

      <p class="text"><span class="yellow">As an alternative to
      definitive circumcision, we propose a trial of Er:YAG laser
      ablation as a low risk, first line treatment of ZB, replacing
      the far more thermally destructive CO<sub>2</sub>
      laser.</span> The Er:YAG laser is ideally suited to
      selectively remove the diseased epithelium of the glans penis
      without risk of scarring. We also emphasize the need for
      histologic confirmation of clinical diagnoses, as this
      patient was referred for Mohs micrographic surgery of EQ that
      was subsequently diagnosed as ZB pathologically.</p>
      <br />

      <h4>REFERENCES</h4>

      <ol>
        <li class="note"><a id="n1" name="n1"></a><!--1.--> Zoon
        JJ. Balanaposthite chronique circonscrite benigne a
        plasmocytes (contra erythroplasie de Queyrat).
        <i>Dermatologica</i> 1952;105:1-7.</li>

        <li class="note"><a id="n2" name="n2"></a><!--2.--> Garnier
        G. Benign plasma-cell erythroplasia. <i>Br J Dermatol</i>
        1957;69:77-80.</li>

        <li class="note"><a id="n3" name="n3"></a><!--3.--> Stern
        JK, Rosen T. Balanitis plasmacellularis circumscripta
        (Zoon&rsquo;s balanitis plasmacellularis). <i>Cutis</i>
        1980;25:57-60.</li>

        <li class="note"><a id="n4" name="n4"></a><!--4.--> Brodin
        MB. Balanitis circumscripta plasmacellularis. <i>J Am Acad
        Dermatol</i> 1980;2:33-35.</li>

        <li class="note"><a id="n5" name="n5"></a><!--5.-->
        Souteyrand P, Wong E, MacDonald DM. Zoon&rsquo;s balanitis
        (balanitis circumscripta plasmacellularis. <i>Brit J
        Dermatol</i> 1981;105:195-199.</li>

        <li class="note"><a id="n6" name="n6"></a><!--6.--> Jolly
        BB, Krishnamurty S, Vaidyanathan S. Zoon&rsquo;s balanitis.
        <i>Urol Int</i> 1993;50:182-184.</li>

        <li class="note"><a id="n7" name="n7"></a><!--7.--> Murray
        JG, Fletcher MS, Yates-Bell AJ, Pryor JP, Darby AJ, Packham
        DA. <i>Brit J Urol</i> 1986;58:689-691.</li>

        <li class="note"><a id="n8" name="n8"></a><!--8.-->
        Yoganathan S, Bohl TG, Mason G. Plasma cell balanitis and
        vulvitis (of Zoon). A study of 10 cases. <i>J Reprod
        Med</i> 1994;39:939-944.</li>

        <li class="note"><a id="n9" name="n9"></a><!--9.--> Horan
        DB, Redman JF, Jansen GT. Papulosquamous lesions of glans
        penis. <i>Urology</i> 1984;23:1-4.</li>

        <li class="note"><a id="n10" name="n10"></a><!--10.-->
        Kumar B, Sharma R, Rajagopalan M, Radotra BD. Plasma cell
        balanitis: clinical and histopahtological features-response
        to circumcision. <i>Genitourin Med</i> 1995;71:32-34.</li>

        <li class="note"><a id="n11" name="n11"></a><!--11.-->
        Baldwin HE, Geronemus RG. The treatment of Zoon&rsquo;s
        balanitis with the carbon dioxide laser. <i>J Dermatol Surg
        Oncol</i> 1989;15:491-494.</li>

        <li class="note"><a id="n12" name="n12"></a><!--12.-->
        Ferrandiz C, Ribera M. Zoon&rsquo;s balanitis treated by
        circumcision. <i>J Dermatol Surg Oncol</i>
        1984;10:622-625.</li>

        <li class="note"><a id="n13" name="n13"></a><!--13.-->
        Sonnex TS, Dawber RP, Ryan TJ, Ralfs IG. Zoon&rsquo;s
        (plasma-cell) balanitis: treatment by circumcision. <i>Brit
        J Dermatol</i> 1982;106:585-8.</li>

        <li class="note"><a id="n14" name="n14"></a><!--14.-->
        Vohra S, Badlani G. Balanitis and balanoposthitis.
        <i>Urologic Clinics of North America</i>
        1992;19:143-147.</li>

        <li class="note"><a id="n15" name="n15"></a><!--15.--> In:
        Montgomery J. <i>Dermatopathology</i>. Vol 2. London:
        Harper &amp; Row. 1967:988.</li>

        <li class="note"><a id="n16" name="n16"></a><!--16.-->
        Petersen CS, Thomsen K. Fusidic acid cream in the treatment
        of plasma cell balanitis. <i>J Am Acad Dermatol</i>
        1992;27:633-4.</li>

        <li class="note"><a id="n17" name="n17"></a><!--17.--> In:
        Walsh PC [et al] ed. Campbell&rsquo;s Urology 7th Ed.
        Philadelphia PA: WB Saunders. 1998:729.</li>

        <li class="note"><a id="n18" name="n18"></a><!--18.-->
        Fitzpatrick RE, Ruiz-Esparza J, Goldman MP. The depth of
        thermal necrosis using the CO<sub>2</sub> laser. <i>J
        Dermatol Surg Oncol</i> 1991;17:340-4.</li>

        <li class="note"><a id="n19" name="n19"></a><!--19.-->
        Kaufmann R, Hartmann A, Hibst R. Cutting and skin ablative
        properties of pulsed mid-infrared laser surgery. <i>J
        Dermatol Surg Oncol</i> 1994;20:112-8.</li>

        <li class="note"><a id="n20" name="n20"></a><!--20.-->
        Walsh JT, Deutsch TF. Er:YAG laser ablation of tissue:
        measurement of ablation rates. <i>Lasers Surg Med</i>
        1989;9:327-37.</li>

        <li class="note"><a id="n21" name="n21"></a><!--21.-->
        Walsh JT, Flotte TJ, Deutsch TF. Er:YAG laser ablation of
        tissue: effect of pulse duration and tissue type on thermal
        damage. <i>Lasers Surg Med</i> 1989;9:314-26.</li>

        <li class="note"><a id="n22" name="n22"></a><!--22.-->
        Kaufmann R, Hibst R. Pulsed Er:YAG and 308 nm UV-Excimer
        laser: an in vitro and in vivo study of skin ablative
        effect. <i>Lasers Surg Med</i> 1989;9:132-40.</li>

        <li class="note"><a id="n23" name="n23"></a><!--23.-->
        Kaufmann R, Hibst R. Pulsed 2.94 um Erbium:YAG laser skin
        ablation: experimental results and first clinical
        application. <i>Clin Exp Dermatol</i> 1990;15:389-93.</li>

        <li class="note"><a id="n24" name="n24"></a><!--24.-->
        Hibst R, Kaufmann R. Effects of laser parameters on pulsed
        Er:YAG laser skin ablation. <i>Lasers Med Sci</i>
        1991;6:391-7.</li>

        <li class="note"><a id="n25" name="n25"></a><!--25.--> Ross
        EV, Naseef GS, McKinlay JR, et al. Comparison of carbon
        dioxide laser, erbium:YAG laser, dermabrasion and
        dermatome. A study of thermal damage, wound contraction,
        and wound healing in a live pig model: implications for
        skin resurfacing. <i>J Am Acad Dermatol</i>
        2000;42:92-105.</li>

        <li class="note"><a id="n26" name="n26"></a><!--26.-->
        Aretz HT, Parham CW, Peretti G, et al. Comparison of
        healing skin lesions induced by Erbium:YAG laser versus
        scalpel. <i>Lasers Surg Med</i> 1989;9:34A.</li>

        <li class="note"><a id="n27" name="n27"></a><!--27.-->
        Jaffe BH, Walsh JT. Water flux from partial-thickness skin
        wounds:comparative study of the effects of Er:YAG and
        Ho:YAG lasers. <i>Lasers Surg Med</i> 1996;18:1-9.</li>

        <li class="note"><a id="n28" name="n28"></a><!--28.-->
        Kaufmann R, Hibst R. Pulsed erbium:YAG laser ablation in
        cutaneous surgery. <i>Lasers Surg Med</i>
        1996;19:324-30.</li>

        <li class="note"><a id="n29" name="n29"></a><!--29.-->
        Alster TS. Clinical and histologic evaluation of six
        erbium:YAG lasers for cutaneous resurfacing. <i>Lasers Surg
        Med</i> 1999;24:87-92.</li>

        <li class="note"><a id="n30" name="n30"></a><!--30.-->
        Hibst R. Stock K, Kaufmann R. Ablation and controlled
        heating of skin with the Er:YAG laser. <i>Lasers Surg
        Med</i> 1997;21(suppl 9):40.</li>

        <li class="note"><a id="n31" name="n31"></a><!--31.-->
        Hohenleutner V, Hohenleutner S, Baumler W, et al. Fast and
        effective skin ablation with an Er:YAG laser: Determination
        of ablation rates and thermal damage zones. <i>Lasers Surg
        Med</i> 1997;20:242-7.</li>

        <li class="note"><a id="n32" name="n32"></a><!--32.-->
        Utley DS, Koch RJ, Egbert BM. Histologic analysis of the
        thermal effect on epidermal and dermal structures following
        treatment with the superpulsed CO2 laser and the erbium:YAG
        laser: an in vivo study. <i>Lasers Surg Med</i>
        1999;24:93.</li>

        <li class="note"><a id="n33" name="n33"></a><!--33.-->
        Khatri KA, Ross EV, Grevelink JM, et al. Comparison of
        erbium:YAG and carbon dioxide lasers in resurfacing of
        facial rhytides. <i>Arch Dermatol</i> 1999;135:391-7.</li>

        <li class="note"><a id="n34" name="n34"></a><!--34.--> de
        Noronha L, Wei Kin Chin E, Menini CM, et al.
        Histopathologic and morphometric evaluation of the skin
        abnormalities induced by erbium:YAG and carbon dioxide
        lasers in 10 patients. <i>Plast Reconstr Surg</i>
        2001;108:1380-8.</li>

        <li class="note"><a id="n35" name="n35"></a><!--35.-->
        Perez M, Bank DE, Silvers D. Skin resurfacing of the face
        with the Erbium:YAG laser. <i>Dermatol Surg</i>
        1998;24:653-659.</li>

        <li class="note"><a id="n36" name="n36"></a><!--36.--> Hale
        GM, Querry MR. Optical constants of water in the 200 nm to
        200 um wavelength region. <i>Appl Optics</i>
        1973;12:555-563.</li>

        <li class="note"><a id="n37" name="n37"></a><!--37.-->
        Walsh JT, Cummings JP. Effect of the dynamic optical
        properties of water on midinfrared laser ablation.
        <i>Lasers Surg Med</i> 1994;15:295-305.</li>

        <li class="note"><a id="n38" name="n38"></a><!--38.-->
        Majaron B, Srinivas SM, Huang HL, et al. Deep coagulation
        of dermal collagen with repetitive Er:YAG laser
        irradiation. <i>Lasers Surg Med</i> 2000;26:215-22.</li>
      </ol>
      <hr width="200" color="black" size="1" align="left" />

      <p class="notes">Address Correspondence to: Maj John G.
      Albertini<br />
       Dept of Dermatology<br />
       <a href="http://www.bamc.amedd.army.mil/"
      target="_blank">Brooke Army Medical Center</a><br />
       Fort Sam Houston, TX 78234<br />
      Phone (210) 916-4408; FAX (210) 916-3103<br />
      <a
      href="mailto:John.Albertini@cen.amedd.army.mil">John.Albertini@cen.amedd.army.mil</a></p>

      <p class="reprints">Transfer of copyright statement: I (we),
      the undersigned author(s), was (were) an employee(s) of the
      US federal government when this work was conducted and
      prepared for publication; therefore, the work lies within the
      public domain and is not subject to the Copyright Act.
      Ownership of copyright cannot be transferred.</p>

      <p class="reprints">Reprints not available</p>

      <p class="reprints">Accepted 6 December 2001.</p>
    </div>
    <hr />
    Citation: 

    <ul>
      <li>Albertini JG, Holck DE, Farley MF. Zoon's balanitis
      treated with Erbium:YAG laser ablation. <i>Lasers Surg
      Med</i> 2002; 30(2):123-6.</li>
    </ul>
    <hr />
    <small>(File created 20 November 2002)</small> 

    <center>
      <p class="navlink"><a href="/library/">Return to CIRP
      Library</a></p>
    </center>

    <p>
    <tt>http://www.cirp.org/library/disease/balantis/albertini1/</tt></p>
  </body>
</html>
